#USA #Berwyn #Nordic Pharma #LACRIFILL #Dry Eye Treatment

Nordic Pharma Reaches Key Milestone with Lacrifill®

Berwyn, PA, April 9, 2026 - Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., proudly announces a monumental achievement in its journey toward improving eye health. The company has successfully treated over 100,000 patients in the United States with its innovative Lacrifill® Canalicular Gel in less than two years since its launch. This gel is designed to address the symptoms of dry eye, which impacts a significant portion of the adult population in the U.S.

In line with its commitment to excellence, Nordic Pharma is enhancing its product offering by including cannulas with every shipment of Lacrifill®. This adaptation, driven by feedback from healthcare providers, aims to increase convenience for practitioners and improve the overall treatment experience for patients.

Dr. Eric Donnenfeld, Chairman of OCLI Vision and NYU Langone Health, emphasized the importance of proactive management in maintaining eye surface health. He noted, "As physicians, we must actively manage our patients' eye surface health and comfort, especially during surgical procedures. Lacrifill® has consistently fulfilled its purpose by providing effective control of the eye surface. It's not just another punctal plug; it is a revolutionary approach to eye surface treatment. It has significantly enhanced my practice."

In addition, Dr. Mile Brujic, OD, FAAO, from Premier Vision Group, shared, "The management of eye surface conditions has become increasingly vital in modern ophthalmology. The use of Lacrifill® has been a game changer in my practice—not only for my routine dry eye patients but also as part of my surgical patient management. It is a critical option as it supports excellent vision outcomes and greatly enhances patient comfort. The clinical data supporting the use of Lacrifill is compelling and substantiates the benefits we observe in our patients."

Lacrifill® is available in pre-filled syringes, each containing sufficient gel to treat the upper and lower canaliculi of both eyes. The gel is introduced into the punctum through a cannula tip, facilitating its flow into the tear sac. The syringes are shipped in packs of ten, which now include ten cannulas to streamline the application process.

Having received FDA approval in May 2024, Nordic Pharma has taken significant steps to ensure that Lacrifill® serves effectively as a temporary blockage to tear drainage through the canaliculi. In the short time since its introduction, the gel has made a notable impact, fulfilling the needs of patients suffering from dry eye, a condition affecting approximately 6.8% of adults in the United States.

Dr. Jai Parekh, Chief Commercial Officer of Eye Care US, stated, "We are thrilled by the quick acceptance of Lacrifill® among so many optometrists and ophthalmologists nationwide. It’s gratifying to know that our innovative treatment has provided relief to many patients in a relatively short period for a condition that significantly affects their quality of life. Lacrifill® signifies a shift toward more intervention-based approaches for managing dry eyes."

Upcoming Demonstrations

Nordic Pharma will conduct live demonstrations of Lacrifill® at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, taking place from April 10th to 13th in Washington, DC. Attendees will have the chance to see Lacrifill® in action at Booth #2307 at scheduled times throughout the conference.